Benign Prostatic Hyperplasia (BPH) Treatment Market Size Analysis Report by Type (Drug Treatment, Surgical Treatment), End User (Home Healthcare, Hospitals & Clinics)

Description

List of Tables

According to the latest market research study published by P&S Intelligence, the BPH treatment market accounted for $11,892.8 million revenue in 2021, which is set to touch $18,837.7 million by 2030, progressing at a 5.2% CAGR from 2021 to 2030. This is owing to the growing cases of BPH, soaring preference for minimally invasive operations, and snowballing investments for research on novel treatments.

As per Medscape, by the age of 60, approximately 50% of the men develop histopathologic BPH. By the age of 85, this percentage rises to 90%.

One way in which BPH management has significantly benefitted from advanced technology is the introduction of procedures that do not require general anesthesia or lengthy hospital stays. The prostate can now be fitted with a cutting-edge mechanical implant, which moves the invading lobes to a better position, to improve urine flow.

Minimally Invasive Procedures Are Gaining Wide Acceptance

Surgery is a superior option to treating BPH with medicine. However, patients tend to choose medication because of the post-operative harm that surgical incisions and burns can cause. Lately, patients' perceptions have changed as a result of the development of minimally invasive techniques, thus giving surgical equipment makers a competitive advantage.

Demand for Alpha-Blockers Rising among Patients

Around 85% of the market share was acquired for drug treatment in 2021. This is due to the rising demand for alpha-blockers, which help facilitate easier urine flow by relaxing the bladder neck muscles and the prostate.

Home Healthcare Settings Will Accumulate More Revenue

Home healthcare settings hold the larger market share, and they will experience a CAGR of over 5% in the coming years. This is owing to the rising number of patients who are being prescribed medications rather than surgical procedures. Additionally, a sizeable section of the populace favors drug-based home therapy over hospital care.

North America Widely Uses BPH Treatment

North America holds a 41% share of the global BPH treatment market. The problem's prevalence is rising, encouraging the use of cutting-edge treatments, including prostatic stenting, laser therapy, and UroLift therapy.

Additionally, there are a number of device and pharmaceutical companies in the region, and they are all keenly interested in undertaking R&D operations to improve the standard of care.

With a CAGR of 6.4%, the APAC region is predicted to grow the quickest. The progress is aided by the expanding standard of living, thriving per capita income and purchasing power, rising urological illness burden, and increasing healthcare investment.

The senior male population in Japan, China, and India is huge and needs constant medical care because of its high tendency for chronic illnesses.

Product Code: 12191

Chapter 1. Research Background

1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
- 1.4.1 Value
1.5 Market Size Breakdown by Segment
- 1.5.1 Market Segmentation by Type
- 1.5.2 Market Segmentation by End User
- 1.5.3 Market Segmentation by Region
1.6 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research
- 2.1.1 Paid
- 2.1.2 Unpaid
- 2.1.3 P&S Intelligence Database
2.2 Primary Research
- 2.2.1 Breakdown of Primary Research, by Designation
- 2.2.2 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
2.6 Notes and Caveats

Chapter 3. Executive Summary

3.1 U.S.
3.2 Canada
3.3 Germany
3.4 France
3.5 U.K.
3.6 China
3.7 Japan
3.8 South Korea
3.9 India

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Definition of Market Segments

5.1 By Type
- 5.1.1 Drug Treatment
  - 5.1.1.1 Alpha blockers
    - 5.1.1.1.1 Alfuzosin
    - 5.1.1.1.2 Doxazosin
    - 5.1.1.1.3 Tamsulosin
    - 5.1.1.1.4 Silodosin
    - 5.1.1.1.5 Other alpha blockers
    - 5.1.1.2 5-Alpha reductase inhibitors
    - 5.1.1.2.1 Finasteride
    - 5.1.1.2.2 Dutasteride
  - 5.1.1.3 Others
- 5.1.2 Surgical Treatment
  - 5.1.2.1 TURP
  - 5.1.2.2 TUMT
  - 5.1.2.3 TUNA
  - 5.1.2.4 Laser therapy
  - 5.1.2.5 Prostatic stenting
  - 5.1.2.6 UroLift therapy
  - 5.1.2.7 Rezum therapy
  - 5.1.2.8 Others
5.2 By End User
- 5.2.1 Home Healthcare
- 5.2.2 Hospitals & Clinics

Chapter 6. Industry Outlook

6.1 Market Dynamics
- 6.1.1 Trends
  - 6.1.1.1 Technological advancements
  - 6.1.1.2 Product approvals and launches
- 6.1.2 Drivers
  - 6.1.2.1 Increasing geriatric male population
  - 6.1.2.2 Rising prevalence of BPH
  - 6.1.2.3 Surging awareness of BPH disorders
- 6.1.3 Impact Analysis of Drivers on Market Forecast
- 6.1.4 Restraints
  - 6.1.4.1 Side-effects associated with BPH medication
  - 6.1.4.2 Unfavorable healthcare reforms
- 6.1.5 Impact Analysis of Restraints on Market Forecast
6.2 Impact of COVID-19
6.3 Porter's Five Forces Analysis
- 6.3.1 Bargaining Power of Buyers
- 6.3.2 Bargaining Power of Suppliers
- 6.3.3 Intensity of Rivalry
- 6.3.4 Threat of New Entrants
- 6.3.5 Threat of Substitutes

Chapter 7. Policy and Regulatory Landscape

7.1 Regulations for BPH Treatment Devices
- 7.1.1 North America
- 7.1.2 Europe
- 7.1.3 APAC
- 7.1.4 LATAM
- 7.1.5 MEA
7.2 Regulatory Framework for Drug Approval
- 7.2.1 U.S.
- 7.2.2 Europe
  - 7.2.2.1 Centralized procedure
  - 7.2.2.2 Mutual recognition procedure
  - 7.2.2.3 Decentralized procedure
  - 7.2.2.4 Nationalized procedure
- 7.2.3 Japan

Chapter 8. Global Market Size and Forecast

8.1 Overview
8.2 Market Revenue, by Type (2015-2030)
- 8.2.1 Global Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 8.2.1.1 Global benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 8.2.1.2 Global benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 8.2.2 Global Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
8.3 Market Revenue, by End User (2015-2030)
8.4 Market Revenue, by Region (2015-2030)

Chapter 9. North America Market Size and Forecast

9.1 Overview
9.2 Market Revenue, by Type (2015-2030)
- 9.2.1 North America Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 9.2.1.1 North America benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 9.2.1.2 North America benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 9.2.2 North America Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
9.3 Market Revenue, by End User (2015-2030)
9.4 Market Revenue, by Country (2015-2030)

Chapter 10. U.S. Market Size and Forecast

10.1 Market Revenue, by Type (2015-2030)
- 10.1.1 U.S. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 10.1.1.1 U.S. benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 10.1.1.2 U.S. benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 10.1.2 U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
10.2 Market Revenue, by End User (2015-2030)

Chapter 11. Canada Market Size and Forecast

11.1 Market Revenue, by Type (2015-2030)
- 11.1.1 Canada Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 11.1.1.1 Canada benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 11.1.1.2 Canada benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 11.1.2 Canada Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
11.2 Market Revenue, by End User (2015-2030)

Chapter 12. Europe Market Size and Forecast

12.1 Overview
12.2 Market Revenue, by Type (2015-2030)
- 12.2.1 Europe Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 12.2.1.1 Europe benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 12.2.1.2 Europe benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 12.2.2 Europe Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
12.3 Market Revenue, by End User (2015-2030)
12.4 Market Revenue, by Country (2015-2030)

Chapter 13. Germany Market Size and Forecast

13.1 Market Revenue, by Type (2015-2030)
- 13.1.1 Germany Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 13.1.1.1 Germany benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 13.1.1.2 Germany benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 13.1.2 Germany Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
13.2 Market Revenue, by End User (2015-2030)

Chapter 14. France Market Size and Forecast

14.1 Market Revenue, by Type (2015-2030)
- 14.1.1 France Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 14.1.1.1 France benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 14.1.1.2 France benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 14.1.2 France Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
14.2 Market Revenue, by End User (2015-2030)

Chapter 15. U.K. Market Size and Forecast

15.1 Market Revenue, by Type (2015-2030)
- 15.1.1 U.K. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 15.1.1.1 U.K. benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 15.1.1.2 U.K. benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 15.1.2 U.K. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
15.2 Market Revenue, by End User (2015-2030)

Chapter 16. APAC Market Size and Forecast

16.1 Overview
16.2 Market Revenue, by Type (2015-2030)
- 16.2.1 APAC Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 16.2.1.1 APAC benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 16.2.1.2 APAC benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 16.2.2 APAC Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
16.3 Market Revenue, by End User (2015-2030)
16.4 Market Revenue, by Country (2015-2030)

Chapter 17. China Market Size and Forecast

17.1 Market Revenue, by Type (2015-2030)
- 17.1.1 China Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 17.1.1.1 China benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 17.1.1.2 China benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 17.1.2 China Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
17.2 Market Revenue, by End User (2015-2030)

Chapter 18. Japan Market Size and Forecast

18.1 Market Revenue, by Type (2015-2030)
- 18.1.1 Japan Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 18.1.1.1 Japan benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 18.1.1.2 Japan benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 18.1.2 Japan Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
18.2 Market Revenue, by End User (2015-2030)

Chapter 19. South Korea Market Size and Forecast

19.1 Market Revenue, by Type (2015-2030)
- 19.1.1 South Korea Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 19.1.1.1 South Korea benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 19.1.1.2 South Korea benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 19.1.2 South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
19.2 Market Revenue, by End User (2015-2030)

Chapter 20. India Market Size and Forecast

20.1 Market Revenue, by Type (2015-2030)
- 20.1.1 India Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 20.1.1.1 India benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 20.1.1.2 India benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 20.1.2 India Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
20.2 Market Revenue, by End User (2015-2030)

Chapter 21. LATAM Market Size and Forecast

21.1 Overview
21.2 Market Revenue, by Type (2015-2030)
- 21.2.1 LATAM Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 21.2.1.1 LATAM benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 21.2.1.2 LATAM benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 21.2.2 LATAM Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
21.3 Market Revenue, by End User (2015-2030)
21.4 Market Revenue, by Country (2015-2030)

Chapter 22. MEA Market Size and Forecast

22.1 Overview
22.2 Market Revenue, by Type (2015-2030)
- 22.2.1 MEA Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
  - 22.2.1.1 MEA benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
  - 22.2.1.2 MEA benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
- 22.2.2 MEA Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
22.3 Market Revenue, by End User (2015-2030)
22.4 Market Revenue, by Country (2015-2030)

Chapter 23. Competitive Landscape

23.1 List of Market Players and Their Offerings
23.2 Market Share Analysis of Key Players
- 23.2.1 Global BPH Drugs Market
- 23.2.2 Global BPH Surgical Treatment Market
23.3 Competitive Analysis of Key Players
23.4 Product Comparison of Key Players
23.5 Recent Strategic Developments of Key Players
- 23.5.1 Partnerships & Acquisitions
- 23.5.2 Geographical Expansions
- 23.5.3 Product Launches
- 23.5.4 Other Developments

Chapter 24. Company Profiles

24.1 Astellas Pharma Inc.
- 24.1.1 Business Overview
- 24.1.2 Product and Service Offerings
- 24.1.3 Key Financial Summary
24.2 Alembic Pharmaceuticals Limited
- 24.2.1 Business Overview
- 24.2.2 Product and Service Offerings
- 24.2.3 Key Financial Summary
24.3 Unilab Inc.
- 24.3.1 Business Overview
- 24.3.2 Product and Service Offerings
24.4 Pharex Health Corporation
- 24.4.1 Business Overview
- 24.4.2 Product and Service Offerings
24.5 Biolitec AG
- 24.5.1 Business Overview
- 24.5.2 Product and Service Offering
24.6 Urologix LLC
- 24.6.1 Business Overview
- 24.6.2 Product and Service Offerings
24.7 Advin Health Care
- 24.7.1 Business Overview
- 24.7.2 Product and Service Offerings
24.8 Asclepion Laser Technologies GmbH
- 24.8.1 Business Overview
- 24.8.2 Product and Service Offerings
24.9 Pnn Medical A/S
- 24.9.1 Business Overview
- 24.9.2 Product and Service Offerings
24.10 Quanta Systems
- 24.10.1 Business Overview
- 24.10.2 Product and Service Offerings
24.11 Abbott Laboratories
- 24.11.1 Business Overview
- 24.11.2 Product and Service Offerings
- 24.11.3 Key Financial Summary
24.12 Asahi Kasei Corporation
- 24.12.1 Business Overview
- 24.12.2 Product and Service Offerings
- 24.12.3 Key Financial Summary
24.13 Richard Wolf GmbH
- 24.13.1 Business Overview
- 24.13.2 Product and Service Offerings
24.14 Boston Scientific Corporation
- 24.14.1 Business Overview
- 24.14.2 Product and Service Offerings
- 24.14.3 Key Financial Summary
24.15 KARL STORZ SE & Co. KG
- 24.15.1 Business Overview
- 24.15.2 Product and Service Offerings
24.16 Teleflex Incorporated
- 24.16.1 Business Overview
- 24.16.2 Product and Service Offerings
- 24.16.3 Key Financial Summary
24.17 Olympus Corporation
- 24.17.1 Business Overview
- 24.17.2 Product and Service Offerings
- 24.17.3 Key Financial Summary
24.18 Pfizer Inc.
- 24.18.1 Business Overview
- 24.18.2 Product and Service Offerings
- 24.18.3 Key Financial Summary
24.19 Merck & Co. Inc.
- 24.19.1 Business Overview
- 24.19.2 Product and Service Offerings
- 24.19.3 Key Financial Summary
24.20 Eli Lilly and Company
- 24.20.1 Business Overview
- 24.20.2 Product and Service Offerings
- 24.20.3 Key Financial Summary
24.21 GlaxoSmithKline plc
- 24.21.1 Business Overview
- 24.21.2 Product and Service Offerings
- 24.21.3 Key Financial Summary
24.22 Allergan plc
- 24.22.1 Business Overview
- 24.22.2 Product and Service Offerings
- 24.22.3 Key Financial Summary
24.23 IPG Photonics Corporation
- 24.23.1 Business Overview
- 24.23.2 Product and Service Offerings
- 24.23.3 Key Financial Summary
24.24 Sanofi
- 24.24.1 Business Overview
- 24.24.2 Product and Service Offerings
- 24.24.3 Key Financial Summary
24.25 Allium Medical Solutions Ltd.
- 24.25.1 Business Overview
- 24.25.2 Product and Service Offerings
24.26 SRS Medical
- 24.26.1 Business Overview
- 24.26.2 Product and Service Offerings
24.27 Convergent Laser Technologies
- 24.27.1 Business Overview
- 24.27.2 Product and Service Offerings

Chapter 25. Appendix

25.1 Sources and References
25.2 Related Reports